Using the Danish nationwide registries, the purpose of this paper was to (1) compare the 1‐year risk of add‐on glucose‐lowering therapy and nonadherence among patients with prediabetes (HbA1c 42–47 mmol/mol) or diabetes (HbA1c ≥ 48 mmol/mol) in first‐line treatment with GLP‐1 RA or metformin. The gene discussed is GLP1R; the disease is diabetes mellitus.